Company record · VRTX · Pharmaceutical Preparations
Vertex Pharmaceuticals
Vertex Pharmaceuticals disclosed a change in its chief financial officer, effective January 1, 2027; the incoming officer named in the filing is Jonathan Poole. Until then the filing lists Charles F. Wagner, Jr. in the role. See the filing record.
Roster record
| Officer | Charles F. Wagner, Jr. |
|---|---|
| Verified | February 13, 2026 (filing date of the source) |
| Note | The DEF 14A filed 2026-04-02 does not name Charles F. Wagner, Jr. near a Chief Financial Officer title; check for a change. An 8-K with Item 5.02 was filed on 2026-09-01, after this 10-K; any CFO change it reports is tracked on the moves record. |
- sec.gov · signature block · “/s/ Charles F. Wagner, Jr. Charles F. Wagner, Jr. Executive Vice President and Chief Operating & Financial Officer (Principal Financial Officer)”
Tracked changes
This record covers what the tracked filings state; it is not a complete history of the company's finance leadership. Spot an error? Send a correction.